Purchasing factor concentrates in the 21st century through competitive tendering
Author:
- 28 May 2013
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 19 (5) , 660-667
Abstract
Summary: The increasing intensity of treatment, the widespread adoption of factor VIII and IX prophylaxis and increasing usage over the past decade have led to haemophilia becoming an almost uniquely expensive condition to treat. The average adult with severe haemophilia A in the UK used 250 000 IU of factor VIII in 2011/2012, at a cost in excess of £100 000 p.a. The cost to the end‐user may be considerably higher than this for some US patients supplied by home care companies with high on‐costs. This has led to a high level of administrative scrutiny of treatment and an imperative to procure clotting factor concentrates more efficiently and collectively. National procurement schemes have run successfully in various countries and will become commoner. The UK system of procurement is described. This system, following EU procurement rules, evaluated products technically and by price. The price of bioequivalent products was determined by reverse e‐auction. Considerable cost reductions were achieved whilst retaining all suppliers and maintaining a degree of prescribing freedom. Elements of this system could be more widely applied.Keywords
This publication has 9 references indexed in Scilit:
- Factor VIII Products and Inhibitor Development in Severe Hemophilia ANew England Journal of Medicine, 2013
- Clotting factor concentrate switching and inhibitor development in hemophilia ABlood, 2012
- Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studiesJournal of Thrombosis and Haemostasis, 2011
- Concentrate‐related inhibitor risk: is a difference always real?Journal of Thrombosis and Haemostasis, 2011
- Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIIIJournal of Thrombosis and Haemostasis, 2011
- Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United KingdomBlood, 2011
- A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucroseHaemophilia, 2008
- Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement TherapyTransfusion Science, 1998
- GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERSHaemophilia, 1997